Dr David Beran
Accès à l'insuline et la problématique de la multimorbidité
David Beran is a Researcher and Lecturer at the Geneva University Hospitals and University of Geneva within the Division of Tropical and Humanitarian Medicine. Before this David was the Project Coordinator of the International Insulin Foundation based at University College London (UCL) where he developed and implemented a health systems tool to assess to access to diabetes care. This work was carried out in Kyrgyzstan, Mali, Mozambique, Nicaragua, Vietnam and Zambia and led to the development of specific policies and projects to address the barriers identified.
David is a Swiss national who grew up in Geneva. He holds a BSc in Management with an Emphasis in Marketing. Following his first degree, he worked for a leading Swiss Biotech Company in both Health Policy and Government Relations and Public Relations. He then obtained his MSc in Public Health at the London School of Hygiene and Tropical Medicine. David’s PhD at UCL researched the needs of people with Type 1 diabetes in 13 countries.
His research interests include: health systems and health systems research; management of chronic diseases; diabetes; patient needs; access to insulin and the issue of multi-morbidity. Together with colleagues David launched in early 2012 the 100 Campaign aimed at raising awareness about the issue of access to insulin.
Current projects include a global survey of barriers to access to insulin, the Addressing the Challenges and Constraints of Insulin Sources and Supply in collaboration with Health Action International and Boston University; Management of Chronic Diseases: the perspective of Primary Care doctors in Geneva and Management of Noncommunicable diseases and Neglected Tropical Diseases in Primary Health Care (Mozambique, Nepal and Peru) funded by the Swiss National Science Foundation. In addition David helps support a project on the reform of Medical education in Kyrgyzstan funded by the Swiss Agency for Development and Cooperation as well as work closely with the WHO on the issues of diabetes and access to medicines for Noncommunicable diseases.